Adage Capital Partners’s Olema Pharmaceuticals OLMA Stock Holding History

Adage Capital Partners’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.1M	Buy	275,000 +65,000	+31%	+$1.45M	0.01%	789
2025 Q4	$5.25M	Buy	+210,000	New	+$3.74M	0.01%	757
2025 Q1	–	Sell	-365,198	Closed	-$2.13M	–	914
2024 Q4	$2.13M	Sell	365,198 -34,802	-9%	-$348K	﹤0.01%	788
2024 Q3	$4.78M	Buy	400,000 +75,000	+23%	+$959K	0.01%	719
2024 Q2	$3.52M	Sell	325,000 -135,000	-29%	-$1.46M	0.01%	743
2024 Q1	$5.21M	Sell	460,000 -40,000	-8%	-$516K	0.01%	695
2023 Q4	$7.01M	Buy	500,000 +111,018	+29%	+$1.49M	0.01%	649
2023 Q3	$4.8M	Buy	388,982 +157,549	+68%	+$1.61M	0.01%	666
2023 Q2	$2.09M	Sell	231,433 -188,567	-45%	-$1.14M	﹤0.01%	739
2023 Q1	$1.46M	Hold	420,000	–	–	﹤0.01%	785
2022 Q4	$1.03M	Hold	420,000	–	–	﹤0.01%	840
2022 Q3	$1.16M	Sell	420,000 -80,000	-16%	-$339K	﹤0.01%	884
2022 Q2	$2.04M	Buy	500,000 +411,203	+463%	+$1.3M	﹤0.01%	878
2022 Q1	$378K	Buy	+88,797	New	+$489K	﹤0.01%	966
2021 Q3	–	Sell	-225,000	Closed	-$6.3M	–	1051
2021 Q2	$6.3M	Buy	+225,000	New	+$6.4M	0.01%	790

Other funds holding OLMA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Adage Capital Partners's OLMA Position: Q1 2026 in Review

Adage Capital Partners increased its Olema Pharmaceuticals (OLMA) stake by 31% in Q1 2026, buying an estimated $1.45M and bringing the position to 275,000 shares worth $4.1M. The position accounts for 0.01% of the portfolio, ranked #789.

Adage Capital Partners first reported a position in OLMA in Q2 2021 and has held it in 15 quarters since. The position peaked at $7.01M in Q4 2023. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

Adage Capital Partners held 275,000 shares of Olema Pharmaceuticals worth $4.1M as of Q1 2026.
Adage Capital Partners bought 65,000 Olema Pharmaceuticals shares in Q1 2026, an estimated $1.45M.
Olema Pharmaceuticals made up 0.01% of Adage Capital Partners's portfolio in Q1 2026, its #789 holding.
Adage Capital Partners first reported a position in Olema Pharmaceuticals in Q2 2021 and has held it in 15 quarters since.
Adage Capital Partners's Olema Pharmaceuticals position peaked at $7.01M in Q4 2023.
195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.